NCT00486642View on ClinicalTrials.gov

Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

August 31, 2015

Study Completion Date

September 30, 2015

Conditions
Hormone-Resistant Prostate CancerRecurrent Prostate Carcinoma
Interventions
DRUG

Bicalutamide

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Pazopanib Hydrochloride

Given PO

OTHER

Pharmacological Study

Correlative studies

Trial Locations (6)

V5Z 4E6

BCCA-Vancouver Cancer Centre, Vancouver

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

K7L 5P9

Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston

N6A 4L6

London Regional Cancer Program, London

K1H 8L6

Ottawa Hospital and Cancer Center-General Campus, Ottawa

M5G 2M9

University Health Network-Princess Margaret Hospital, Toronto

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00486642 - Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy | Biotech Hunter | Biotech Hunter